乌司奴单抗在炎症性肠病妊娠患者中的前瞻性多中心队列研究
多中心前瞻性队列研究纳入2019至2021年妊娠期接受乌司奴单抗(UST)治疗的炎症性肠病(IBD)患者,按1:2匹配对照,比较UST、抗肿瘤坏死因子α(anti-TNF)及非UST非anti-TNF治疗者的母婴结局,随访新生儿至12个月。结果显示各组妊娠、新生儿及婴儿结局均满意,无显著差异,数据对妊娠期考虑UST的患者和医生具有安抚意义。
要点
- 共纳入129例妊娠IBD患者:UST组27例、anti-TNF组52例、非UST非anti-TNF组50例。
- 产科母体并发症、早产、低出生体重及新生儿第一年住院率在组间均无显著差异。
- UST组妊娠及新生儿结局良好,与anti-TNF或其他治疗相当。
核心结论
- 妊娠期接受UST治疗的IBD患者妊娠及新生儿结局良好,与anti-TNF或其他治疗相当,数据对患者和医生具有安抚意义。
研究设计与样本
- 多中心前瞻性队列研究,2019至2021年招募妊娠期接受UST治疗的IBD女性,并与anti-TNF及非UST非anti-TNF治疗者比较。
- UST组按年龄、体重指数和产次1:2匹配对照,新生儿随访至12个月。
- 共纳入129例妊娠患者:UST组27例、anti-TNF组52例、非UST非anti-TNF组50例(硫嘌呤或美沙拉秦30例、无治疗20例),克罗恩病25例(96.9%)。
主要发现
- 产科母体并发症:UST组3例(11.5%)vs anti-TNF组12例(23.1%)vs 非UST非anti-TNF组4例(8.2%),p=0.095。
- 早产:UST组1例(4.3%)vs anti-TNF组9例(18.4%)vs 非UST非anti-TNF组4例(5.7%),p=0.133。
- 低出生体重:UST组1例(4.2%)vs anti-TNF组5例(10.2%)vs 非UST非anti-TNF组4例(8.3%),p=0.679。
- 新生儿第一年住院:UST组2例(9.1%)vs anti-TNF组4例(8.2%)vs 非UST非anti-TNF组3例(6.1%),p=0.885。
临床怎么用
- 作者认为,妊娠期IBD患者考虑使用UST时,本研究数据具有安抚意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with inflammatory bowel diseases (IBD) often receive biologics to maintain remission during pregnancy. AIMS: To assess maternal and neonatal outcomes in patients with IBD treated with ustekinumab (UST) during pregnancy METHODS: In a multicentre, prospective cohort study, we recruited women with IBD treated with UST during pregnancy between 2019 and 2021. Outcomes were compared among patients treated with UST, anti-tumour necrosis factor α, (anti-TNF) and non-UST, non-anti-TNF therapies. UST-treated patients were matched 1:2 to controls according to age, body mass index and parity. Newborns were followed up to 12 months. RESULTS: We recruited 129 pregnant patients: UST 27; anti-TNF 52; non-UST, non-anti-TNF 50 (thiopurine or mesalazine 30, no therapy 20); Crohn's disease 25 (96.9%). Overall, pregnancy, neonatal and newborn outcomes were satisfactory, with no significant differences among patients treated with UST, anti-TNF and non-UST non-anti-TNF agents for obstetrical maternal complications [UST 3 (11.5%), anti TNF 12 (23.1%), non UST, non-anti-TNF 4 (8.2%), p = 0.095], pre-term delivery [1 (4.3%), 9 (18.4%), 4 (5.7%), p = 0.133], low birth weight [1 (4.2%), 5 (10.2%), 4 (8.3%), p = 0.679], or first year newborn hospitalisation [2 (9.1%), 4 (8.2%), 3 (6.1%), p = 0.885]. CONCLUSION: Pregnant patients with IBD treated with UST demonstrated favourable pregnancy and neonatal outcomes that were comparable with those in patients treated with anti-TNF or other therapy. Data are reassuring for patients with IBD and their physicians when considering UST during pregnancy.
引用
- Avni-Biron I, Mishael T, Zittan E, et al. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2022. PMID: 36168705. doi:10.1111/apt.17224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。